Pharmacological Properties and Molecular Mechanisms of Thymol: Prospects for Its Therapeutic Potential and Pharmaceutical Development By Mohamed Fizur Nagoor Meeran, Hayate Javed, Hasan Al Taee, Sheikh Azimullah, Shreesh K. Ojha Published in: Frontiers in Pharmacology DOI: 10.3389/fphar.2017.00380 ABSTRACT Thymol, chemically known as 2-isopropyl-5-methylphenol is a colorless crystalline monoterpene phenol. It is one of the most important dietary constituents in thyme species. For centuries, it has been used in traditional medicine and has been shown to possess various pharmacological properties including antioxidant, free radical scavenging, anti-inflammatory, analgesic, antispasmodic, antibacterial, antifungal, antiseptic and antitumor activities. The present article presents a detailed review of the scientific literature which reveals the pharmacological properties of thymol and its multiple therapeutic actions against various cardiovascular, neurological, rheumatological, gastrointestinal, metabolic and malignant diseases at both biochemical and molecular levels. The noteworthy effects of thymol are largely attributed to its anti-inflammatory (via inhibiting recruitment of cytokines and chemokines), antioxidant (via scavenging of free radicals, enhancing the endogenous enzymatic and non-enzymatic antioxidants and chelation of metal ions), antihyperlipidemic (via increasing the levels of high density lipoprotein cholesterol and decreasing the levels of low density lipoprotein cholesterol and low density lipoprotein cholesterol in the circulation and membrane stabilization) (via maintaining ionic homeostasis) effects. This review presents an overview of the current in vitro and in vivo data supporting thymol’s therapeutic activity and the challenges concerning its use for prevention and its therapeutic value as a dietary supplement or as a pharmacological agent or as an adjuvant along with current therapeutic agents for the treatment of various diseases. It is one of the potential candidates of natural origin that has shown promising therapeutic potential, pharmacological properties and molecular mechanisms as well as pharmacokinetic properties for the pharmaceutical development of thymol. INTRODUCTION Extensive epidemiological and experimental studies have suggested the health benefits of medicinal herbs as well as their constituents against various human ailments (Sofowora et al., 2013). The therapeutic importance of plants have been quoted in the ancient cultures and traditions of many countries and societies and they are believed to be cost effective and safe. Since ancient times, plants and their products are used as a culinary preparation or as a remedy in different traditional medicine for many diseases (Rahmani et al., 2014). Turmeric, oregano, thyme, olives and dates, to name a few, have been used extensively for culinary purposes in diets and are also believed to possess beneficial effects against numerous diseases (Rahmani et al., 2014). Among these spices, the Greeks, Romans, and Egyptians have used thyme as a preservative, odorant and flavoring agent in foods. It is a small subshrub abundantly used as a traditional medicine in the western Mediterranean region and its leaves are often used as herbal medicinal products and food additives (Zarzuelo and Crespo, 2002). Thyme possesses potent antibacterial, antifungal, sedative, antiseptic, antioxidative, expectorant, antispasmodic, antifungal, antivirotic, antihelminthic, carminative and diaphoretic effects (Rustaiyan et al., 2000; Soliman and Badeaa, 2002). Thyme contains abundant amount of terpenoids, flavonoids, glycosides and phenolic acids (Vila, 2002). Among many constituents, thymol, chemically known as 2-isopropyl-5-methylphenol is a dietary monoterpene phenol and is abundantly found in certain plants such as Thymus vulgaris (Amiri, 2012), Ocimum gratissimum (Pandey et al., 2014), Thymus ciliates (Kabouche et al., 2009), Satureja thymbra (Markovic et al., 2011), Thymus zygis (Ocana and Reglero, 2012), Trachyspermum ammi (Bairwa et al., 2012), Carum copticum (Khajeh et al., 2004), Satureja intermedia (Yousefzadi et al., 2012), Thymbra capitata (Miguel et al., 2015), Lippia multiflora (Ku and Lin, 2013), Thymus pectinatus (Vardar-Unlu et al., 2003), Zataria multiflora (Veras et al., 2013), Satureja hortensis (Soran and Lung, 2010), Centipeda minima (Liang et al., 2007) and Nigella sativa seeds (Ghosheh et al., 1999). Thymol possesses antibacterial (Didri et al., 1994), antifungal (Mahmoud, 1994), anti-inflammatory (Aeschbach et al., 1994), antioxidant (Yanishlieva et al., 1999), anti-mutagenic (Zahin et al., 2010), larvicidal (Pavela, 2009), analgesic (Ozen et al., 2011), anti-microbial (Karpanen et al., 2008), acaricidal (Araujo et al., 2015), anticonvulsant, antiepileptogenic (Sancheti et al., 2014), wound healing (Riella et al., 2012), anti-hemolytic (Alinezhad et al., 2013), antiphlogistic (Anamura, 1989), antileishmanial (Robledo et al., 2005) and radioprotective (Archana et al., 2011a) properties. Thymol improves digestion by relaxing smooth muscles, prevents menstrual cramps, attenuates respiratory problems and is an active ingredient used in food flavorings, topical ointments, various soaps, toothpastes, shampoos, deodorants and mouthwashes (Shapiro et al., 1994; Manou et al., 1998). Due to its potent antimicrobial properties, thymol is frequently used in dentistry for the treatment of oral cavity infections (Maruniak et al., 1992; Shapiro and Guggenheim, 1995; Twetman et al., 1995; Ogaard et al., 1997; Khan et al., 2017). These pharmacological properties of thymol are ascribed to the pharmacophore of the phenolic hydroxyl group in its chemical structure. The compounds containing the phenolic groups are known to confer protection against the deleterious effects of free radicals both by absorbing or neutralizing free radicals and by augmenting endogenous antioxidants (Wojdylo et al., 2007). Thymol is biosynthesized by the hydroxylation of p-cymene after the aromatization of γ-terpinene to p-cymene (Poulose and Croteau, 1978). The lethal dose (LD50) value of thymol for rats and guinea pigs is 980 mg/kg and 88 mg/kg, body weight, respectively (Jenner et al., 1964). For male and female ddY mice the LD50 is 1200 and 1050 mg/kg, respectively (Hasegawa et al., 1989), whereas the LD50 for cats, rabbits and mice are 250 mg/kg, 750 mg/kg and 640 mg/kg, respectively (Instituto Superiore di Sanita, 1999). The time-tested safety and activity of thymol can also be attested to by the use of thymol for centuries in different cultures and civilizations. One example is the use of thymol containing herbs by the ancient Egyptians for the preservation of mummies. According to the Environmental Protection Agency, there are no known adverse effects with respect to thymol when used in animals and humans. Thymol is cataloged by the United States Food and Drug Administration as ‘Generally Recognized As Safe’ for use as a food additive, therefore it is considered to be safe with negligible toxicity. An extensive literature survey has revealed some excellent reviews on essential oils regarding their phytochemical and pharmacological activities based on their various pharmacological properties. There is a short review describing the therapeutic and pharmacological effects of thymol (Parasei et al., 2016) and a detailed one presenting the antimicrobial properties of thymol (Marchese et al., 2016). But there are no reviews that have been published focusing on the multi-pharmacological properties of thymol against various human ailments until now. Thus, thist review aims to reveal the various pharmacological activities and therapeutic potential of thymol as well as prospects for its pharmaceutical development followed by its mechanism of action demonstrated in both in vivo and in vitro studies. Chemistry and Physical Characteristics of Thymol Thymol (2-isopropyl-5-methylphenol) is a white crystalline substance that gives thyme its strong flavor, pleasant aromatic odor and strong antiseptic property. Its density at 25°C is 0.96 g/cm3 with a melting point ranging from 49°C to 51°C (322-324 K; 120-124°F) (Jordan et al., 1991; Lide and Frederikse, 1996). It is highly soluble in alcohols, alkaline solutions and other organic solvents due to the deprotonation of phenol but it is slightly soluble in water at neutral pH and it absorbs maximum UV radiation at 274 nm (Norwitz et al., 1986; Wade and Reynolds, 1997). It has low solubility in water and its unpleasant taste and smell makes it less palatable (Nieddu et al., 2014). It also has low solubility in the hydrophobic domain of the bacterial cytoplasmic membrane due to its hydrophobicity (Trombetta et al., 2005). For the past few decades, the synthesis of thymol has been achieved using the reaction between p-cymene and m-cresol with isopropyl alcohol or propene and by the use of supercritical CO2 (Amandi et al., 2005; Nagle et al., 2013). Thymol is an important agent of natural origin and has generated interest in the scientific community in pharmacological studies for its therapeutic potential in different diseases. The present review presents an overview of its preclinical data, pharmacokinetics, pharmacological properties and therapeutic potential in different human diseases. Pharmacokinetics of Thymol Absorption Previous reports have revealed the rapid absorption of thymol following oral administration and its degradation in the stomach or intestine (Michiels et al., 2008; Anderson et al., 2012). A report from Schroder and Vollmer (1932) has evidenced the presence of thymol in the stomach, intestine, and urine after its oral administration with sesame oil at a dose around 500 mg in rats and 1–3 g in rabbits. A single dose of thymol (1 or 3 g) encapsulated in gelatin capsule administered to dogs showed the presence of thymol conjugates in urine (22 or 34%) after 3–4 h following urine and fecal analysis (Robbins, 1934). Oral administration of a single dose of thymol (50 mg/kg) was rapidly absorbed and slowly eliminated approximately within 24 h (Nieddu et al., 2014). The maximum concentration (Tmax) was reached after 30 min, while approximately 0.3 h was needed for the half-life of the absorption phase (t1/2). The lower concentrations of thymol were recovered in the liver, lungs, kidneys, and muscles while its higher concentrations were detected in the mucosa and other inner contents of the intestines indicating its partial absorption (Nieddu et al., 2014). According to the report of Kohlert et al. (2002), after the intake of one Bronchipret® TP tablet that is equivalent to 1.08 mg of thymol, the plasma concentrations of thymol metabolites were detectable after 20 min. The rapid absorption of thymol indicates that it’s mainly absorbed in the upper component of the gut. In healthy volunteers, the oral administration of one Bronchipret® TP tablet resulted in a peak plasma concentration (Cmax) of 93.11 ng/ml, Tmax of 1.97 h, t1/2 of 10.2 h, area under time curve from time 0 to clast (AUC0→clast of 837.3 ngh/ml, mean residence time after extravascular administration (MRTabs) of 12.6 h and a mean absorption time (MAT) of 0.53 h (Kohlert et al., 2002). It also had a total body clearance of 1.2 l/h, volume of distribution at steady state of 14.7 l and a volume of distribution during the elimination phase of 17.7 h was reported in healthy humans (Kohlert et al., 2002). Distribution Free thymol is usually not detectable in human plasma. It is circulated as thymol sulfate, not glucuronide, in the blood stream as detected by liquid chromatography-mass spectrophotometry/mass spectrophotometry (LC-MS/MS). Thymol sulfate has been detected in plasma 20 min after administration. The maximum plasma levels (93.1 ± 24.5 ng/ml) of thymol were reported after 1.97 ± 0.77 h of administration. After administration the bioavailability of thymol measured in plasma as thymol sulfate was found to be about 16%. It is eliminated by kidneys and is measured in the urine as thymol conjugates. The volume of distribution (Vdss/f) of 14.7 L has revealed that thymol sulfate mainly resides in the extracellular space (Kohlert et al., 2002). Metabolism Thymol undergoes glucuronidation by uridine 5′-diphospho-glucuronosyltransferase (UGT) following secretion into the proximal tubule (Raoof et al., 1996; Shipkova et al., 2001). The absence of thymol glucuronide in plasma could be due to the lower activity of hepatic UGT compared to sulfotransferase and the formation of glucuronide was shown only at much higher doses (Ogata et al., 1995). In healthy human volunteers, thymol (0.6 g/kg) was metabolized to thymol sulfate, thymol glucronide and thymol thymohydroquinone sulfate and it was excreted in urine (Takada et al., 1979). Elimination The elimination of thymol conjugates in urine was detectable for the first 24 h, with the majority being eliminated after 6 h. The combined amount of both thymol sulfate and glucuronide excreted in urine during the first 24 h was 16.2 ± 4.5% of thymol intake. The renal clearance was calculated to be 0.271 ± 0.7 L/h (Kohlert et al., 2002). Takada et al. (1979) studied the metabolism of thymol in rabbits and humans, wherein thymol (0.5 g/kg) fed to rabbits metabolized to thymol glucuronide as the main metabolite of thymol and eliminated as glucuronic acid and sulfuric acid metabolites (Takada et al., 1979). Austgulen et al. (1987) reported the rapid excretion of thymol and its metabolites in the urine of male albino Wistar rats after thymol was dosed by gavage (1 mM/kg) as analyzed by capillary gas chromatography–mass spectrometry (GC-MS). Williams (1959) summarized the previous reports on the metabolism of thymol and reported its excretion as sulfate and glucuronide conjugates in the urine of dogs, rats and humans. Around 1g (one third) of the dose was excreted in the urine of dogs while feces were found to be devoid of thymol (Robbins, 1934). Pharmacological Properties of Thymol Antioxidant Properties The antioxidant properties of thymol have been well documented in various preclinical studies including cell lines and animal models. At high rate constants, it effectively scavenged the hydroxyl free radicals thereby producing major transient species named phenoxyl radicals. The generated adducts from the phenoxyl radicals undergo dehydration which can be accelerated by an alkaline medium. The addition of hydroxyl radicals at the ortho position (C6 atom) of the phenolic group yields the phenoxyl radical after dehydration. The attack at the ortho position is more favorable energetically while the attack at the para position is also expected to occur. Furthermore, additions at the ortho positions occur without any precomplex formation. The non-toxicity and redox potential of the thymol•/thymol couple makes it a promising antioxidant (Venu et al., 2013). One of the most studied effects of thymol includes the scavenging of free radicals by increasing the activities of several endogenous antioxidant enzymes levels viz. superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), glutathione-S-transferase (GST) along with non-enzymatic antioxidants such as vitamin C, vitamin E and reduced glutathione (GSH) (Nagoor Meeran and Prince, 2012). A comparative study revealed that thymol has superior reducing power, DPPH, superoxide and hydroxyl radical scavenging activity and bestows protection against oxidative damage to lipids (Nagoor Meeran et al., 2015b). The various supportive evidences for the antioxidant activity of thymol are detailed below. In Vitro Studies Thymol was shown to exhibit potent superoxide anion, hydroxyl and DPPH radical scavenging and reducing capacity in a concentration dependent manner (Nagoor Meeran and Prince, 2012; Nagoor Meeran et al., 2015b, 2016b). Thymol possesses SOD like activity in removing superoxide radicals in vitro (Kruk et al., 2000). It has also shown moderate antioxidant activity in V79 Chinese hamster lung fibroblast cells (Undeger et al., 2009). Thymol (25 μg/ml) showed potent antioxidant activity by modulating the activities of enzymatic antioxidants and decreased lipid peroxidation in gamma ray induced V79 Chinese hamster cells (Archana et al., 2011b). Thymol (0.02–0.20%) showed better antioxidant capacity than its isomer carvacrol in lipid systems due to its greater steric hindrance and it was shown that at room temperature it inhibited the autoxidation of two lipid systems namely triacylglycerols of lard (TGL) and triacylglycerols of sunflower oil (TGSO). Furthermore, it also inhibited the oxidation of TGL and TGSO, with potent antioxidant activity against TGSO. Thymol increased chain initiation during the oxidation of TGSO more so than during the oxidation of TGL (Yanishlieva et al., 1999). In the intestinal Caco-2 cell line, thymol (250 μM) attenuated oxidative stress induced by hydrogen peroxide (H2O2) (Cabello et al., 2015). Thymol (250 and 500 μM) strongly inhibited nicotinamide adenine dinucleotide phosphate reduced (NADPH)-cytochrome-c reductase mediated lipid peroxidation isolated from detergent solubilized liver microsomes of rats (Kamataki et al., 1978). Thymol attenuated the production of reactive oxygen species (ROS) and showed myeloperoxidase inhibitory activity in human neutrophils (Perez-Roses et al., 2016). In Vivo Studies Owing to its potent antioxidant potential, thymol showed radioprotective and anticlastogenic potential in gamma radiation induced Swiss albino mice (Archana et al., 2011b). Thymol supplementation increased the antioxidant status and decreased malondialdehyde (MDA) levels in broiler chickens (Zidan et al., 2016). Dietary supplementation with the combination of carvacrol–thymol (1:1) (100 mg/kg) reduced the occurrence of oxidative stress and the impairment of the intestinal barrier in weaning piglets by its potent antioxidant property (Wei et al., 2016). Thymol (24.7 mg/kg) attenuated aflatoxin-induced oxidative stress in male rats due to its potent antioxidant activity (El-Nekeety et al., 2011). Thymol (7.5 mg/kg) has been shown to inhibit lipid peroxidation, glycation, dyslipidemia, inflammation, ionic homeostasis malfunction and apoptosis by virtue of its potent antioxidant property (Nagoor Meeran and Prince, 2012; Nagoor Meeran et al., 2014, 2015b,c, 2016b). Anti-inflammatory Properties Thymol (150 μM) has been shown to ameliorate LPS-induced inflammation in murine macrophage cell lines (Chauhan et al., 2014). Thymol (84 μg/ml) treatment attenuated lipopolysaccharide (LPS) and interferon gamma (IFN-γ) induced macrophage inflammation in vitro by inhibiting messenger RNA expression of inducible nitric oxide (NO) in J774A.1 cell lines (Vigo et al., 2004). In human polymorphonuclear neutrophils (PMNs), thymol (10 and 20 μg/ml) inhibited the synthetic chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced release of elastase, a marker of inflammatory diseases and a serine proteinase released by activated human neutrophils in a concentration-dependent manner (Braga et al., 2006). Thymol (100 μM) has been reported to alter prostaglandin catalyzed biosynthesis by inhibiting both isoforms of cyclooxygenase (COX), with the most active being against COX-1 with an IC50 value of 0.2 μM. These studies suggest the potential of thymol as an anti-inflammatory drug and indicate that it could be used in a similar fashion to non-steroidal anti-inflammatory drugs (Marsik et al., 2005). Thymol (1.1 μg/ml) exhibited inhibitory effects against arachidonic-acid-induced blood coagulation and platelet aggregation in vitro (Enomoto et al., 2001). Thymol (50–150 μM) attenuated bleomycin induced genotoxicity in human ovarian cells (SKOV-3) by virtue of its antioxidant and anti-inflammatory properties (Arab et al., 2015). Ku and Lin (2013) reported the anti-inflammatory nature of thymol by its inhibiting of the T cell immune response and improved T-helper cells-1 (Th1) (interleukin-2 (IL-2) and IFN-γ/T-helper cells-2 (Th2) (interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-10 (IL-10) ratio in mouse primary splenocytes. Thymol (40 μg/ml) inhibited the LPS stimulated inflammatory response in mouse mammary epithelial cells mediating the down regulation of mitogen-activated protein kinases (MAPK) and nuclear factor-kB (NF-κB) signaling pathways (Liang et al., 2014). Thymol (7.5 mg/kg) abrogated the induction of inflammation in isoproterenol (ISO) challenged rats, an animal model of myocardial infraction (MI), which had developed myocardial necrosis. (Nagoor Meeran et al., 2015b). Thymol isolated from essential oils of Lippia gracilis leaves has been shown to inhibit carrageenan-induced edema formation in the paws (administered at the dose of 200 mg/kg) similar to the activity of positive control acetylsalicylic acid (300 mg/kg) (Mendes et al., 2010). Furthermore, treatment with this essential oil at the dose of 50, 100, and 200 mg/kg abrogated leukocyte migration into the peritoneal cavity in carrageenan-challenged experimental animals. Treatment with the essential oil also inhibited the occurrence of abdominal writhes in experimental animals induced by acetic acid. Thymol isolated from leaf essential oils of Lippia gracilis (32.68%) is believed to be primarily responsible for its antinociceptive and anti-inflammatory actions (Mendes et al., 2010). It has been shown to inhibit the release of arachidonic acid, COX and the biosynthesis of prostaglandins such as prostaglandin E2 (PGE2) in the visceral pain model (Mendes et al., 2010). Monteiro et al. (2007) has demonstrated the anti-inflammatory effect of thymol present in the Lippia sidoides essential oil administered at the doses of 1 and 10 mg/ear in the acute ear edema model induced by 12-O-tetradecanoyl phorbol 13-acetate (TPA) in mice as evidenced by reduced edema (a 45.93 and 35.26% reduction, respectively). Thymol (100 mg/kg) attenuated inflammation and promoted wound healing in several rodent models via inhibiting the influx of leucocytes to the injured areas and thus preventing edema (Riella et al., 2012). Thymol exhibited potent anti-inflammatory activity by diminishing the release of inflammatory mediators viz. prostanoids, interleukins and leukotrienes in the buccal sites of young adults (Skold et al., 1998; Yucel-Lindberg et al., 1999). Thymol (10–250 μg/pellet) also elicited potent anti-inflammatory and antiangiogenic action in chorioallantoic membrane (CAM) assay using the experiment model of CAM of the fertilized hen’s egg (Demirci et al., 2004). Thymol (50 μg/ml) increased the mean fluorescence intensity (MFI) of cluster of differentiation 40 (CD40), cluster of differentiation 86 (CD86) and major histocompatibility complex-II (MHCII) expressions determined by flow cytometric analysis in the dendritic cells isolated from spleen of BALB/c mice (Amirghofran et al., 2016). Thymol inhibited ROS (IC50= 3 μg/ml), reactive nitrogen species (RNS) (IC50= 4.7) and significantly reduced generation of NO and H2O2 as well as activities of nitric oxide synthase (NOS) and nicotinamide adenine dinucleotide reduced oxidase (NADH oxidase) in LPS-induced murine macrophages (Kavoosi et al., 2012). A report from Hejazian (2006) has revealed that thymol present as an important constituent in the essential oil of Carum copticum (20 mg/kg) significantly diminished pain sensation in the inflammatory phase of the formalin test in mice. Lorente et al. (1989) revealed an important pharmacological advantage of the potentiation of anti-inflammatory activity of α and β-pinene mixtures (80 mg/kg) upon use in conjunction with thymol (1 mg/kg) in female Wistar rats. Thymol (10 and 20 μg/ml) reduced inflammatory responses through modulation of the expression of c-Jun N-terminal kinase (JNK), stress-activated protein kinases (STAT-3), activator protein-1 (AP-1) and nuclear factors of activated T-cells (NFATs) in LPS treated macrophages (Gholijani et al., 2016). Thymol (600 μM) reduced immunoglobulin-E (IgE)-dependent responses in mast cells through the activation of apoptotic cell death in bone marrow-derived mast cells (BMMCs) and BALB/c mice (Wechsler et al., 2014). Immunological Properties Thymol (25–200 mg/kg) was shown to modulate the immune system in cyclosporine-A treated Swiss albino mice by enhancing the expressions of cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8) and Th1 cytokines via upregulation of IFN-γ expression and enhanced secretion of interleukin-12 (IL-12) (Chauhan et al., 2010). Khajeali et al. (2012) reported that thymol produced a significant increase in antibody titers against the Newcastle disease virus in broiler chickens. Thymol feed supplementation (0–200 mg/kg) improved the activities of digestive enzymes, growth indices and antioxidant status with declined MDA levels. It also improved the immune response via increasing tolerance to hypersensitivity and immunoglobulin G (IgG) in broiler chickens (Hashemipour et al., 2013). It improved innate immunity (Giannenas et al., 2012). Thymol diet supplementation (1%) enhanced the levels of immunoglobulin A (IgA) and immunoglobulin M (IgM) in the sera of weaning pigs challenged with Salmonella typhimurium (Trevisi et al., 2010). Thymol treatment in low-weight growing-finishing pigs raised the percentage of CD4+, CD8+, and MHC-II in their peripheral blood and it also down regulated tumor necrosis factor-α (TNF-α) expression in the stomach of post-weaned pigs (Taranu et al., 2012). Thymol (IC50= 7.69 μg/ml) suppressed the adhesion and superoxide production on isolated ovine neutrophils and also anti-inflammatory property on sheep neutrophils (Farinacci et al., 2008). Thymol has been shown to improve the immune system by increasing the levels of IgA and IgM in the pig’s gut (Li et al., 2012). Thymol (10 μg/ml) attenuated the maturation of dendritic cells and inhibited the mitogenic and allogenic T cell responses along with the secretion of IFN-γ and IL-4 cytokines (Amirghofran et al., 2016). Thymol (10 μg/ml) increased phagocytosis by enhancing the membrane fluidity of macrophages and suppressed the inflammatory responses by downregulating the secretion of pro-inflammatory cytokines by its potent immunostimulating effect (Chauhan et al., 2014). Antimicrobial Properties There are a convincing number of studies that reveal that thymol alone or thymol in plants along with other metabolites possess potent antimicrobial, antifungal, antibacterial, and antiparasitic properties. Marchese et al. (2016) has comprehensively reviewed the antimicrobial properties of thymol. Thymol (32.55%) present in the essential oil of Thymus vulgaris L. showed bacteriostatic activity against most of the gram positive and negative bacteria (Marino et al., 1999). A report from Olasupo et al. (2003) revealed the antibacterial effect of thymol with the lowest minimum inhibitory concentration (MIC) values of 1.0 mmol/L (S. typhimurium) and 1.2 mmol/L (Escherichia coli). Thymol possesses antimicrobial activity against S. aureus (MIC: 0.31 mg/ml) and E. coli (MIC: 5.00 mg/ ml) by the perturbation of the lipid fraction of the bacterial plasma membrane resulting in the leakage of intracellular materials (Trombetta et al., 2005). The thymol chemotypte of the essential oils of T. zygis and T. vulgaris has shown antibacterial effect against various gram negative and positive bacterial strains with MIC ≤ 0.2 μl/ml (Rota et al., 2008). Thymol (200 mg/ml) could inhibit the growth of E. coli. by inducing the permeabilization and depolarization of the cytoplasmic membrane (Xu et al., 2008). Thymol at 2.5 mM inhibits the growth of S. aureus, E. coli and S. typhimurium. Furthermore, a synergistic interaction was found for thymol with all antibiotics tested against E. coli, S. typhimurium, S. aureus, and S. pyogenes (Palaniappan and Holley, 2010). Thymol ester derivatives were found to be more effective against streptococcus species (Mathela et al., 2010). Thymol was found to possess antibacterial activity against selected verocytotoxigenic E. coli (Rivas et al., 2010). Thymol (0.12%) possess antifungal activity against C. albicans MTCC 227 biofilm inhibition (Pemmaraju et al., 2013). Gelatin films containing different thymol concentrations (1–8%) produced inhibitory zones ranging from 30 to 46 mm against several bacteria. Thymol was more effective against Gram positive strains (Kavoosi et al., 2013). Thymol (15 and 30 mg/kg) was shown to possess cytotoxic and antileishmanial activities in hamsters experimentally infected with Leishmania (Viannia) panamensis (Robledo et al., 2005). Thymol derivative named benzoyl-thymol was the best inhibitor (8.67 ± 0.28 μg/mL) against Leishmania infantum chagasi (de Morais et al., 2014). Other Pharmacological Properties The blocking effect of thymol on voltage-activated sodium currents has been investigated in the in vitro setup using experimental cell models of animal and human origin. For skeletal muscle and the neuronal sodium channel, it showed a half-maximum blocking concentration (IC50) of 104 and 149 μM, respectively. Blockade of voltage-operated sodium channels were attributed to confer the antinociceptive and anesthetic effects (Haeseler et al., 2002). In rat skeletal muscle fibers isolated enzymatically, thymol (30–600 μg) treatment suppressed both calcium (Ca2+) and potassium (K+) currents in a concentration-dependent manner with half-maximal effect (EC50) values of 193 ± 26 and 93 ± 11 μM and Hill coefficients of 2.52 ± 0.29 and 1.51 ± 0.18 respectively (Szentandrassy et al., 2003). Thymol has been shown to accelerate K+-induced contracture in skeletal muscle and inhibit Ca2+-binding by the fragmented sarcoplasmic reticulum thus causing the suppression of relaxation (Ebashi, 1965). Thymol (224 μM) was able to invoke the release of Ca2+ with an EC50 value of 158 ± 16 μM and activate ryanodine receptors in heavy sarcoplasmic reticulum vesicles isolated from skeletal muscle which were loaded with Ca2+ (Sarkozi et al., 2007). Thymol (30 μM) was found to increase the depolarization-induced release of Ca2+ from the sarcoplasmic reticulum in rodents (Szentesi et al., 2004). Thymol, at micro concentrations, reduced calcium dependent adenosine triphosphatase (Ca2+-ATPase) activity and increased the permeability of Ca2+ in the sarcoplasmic membrane and it was found to increase the Ca2+ concentrations of neurons or of smooth muscle preparations (Hisayama and Takayanagi, 1986; Kostyuk et al., 1991). Thymol has agonistic effects for the adrenergic receptors (α1, α2, and β) on the circular smooth-muscle strips (SMAs) isolated from stomach and vena portae of guinea pigs. Thymol (10-4 M) inhibits spontaneous contractile activity of the SMAs (100%) and diminishes the excitatory effect of acetylcholine chloride to 35%. Thymol via its influence on nerve cell α2-adrenergic receptors showed an analgesic effect (Beer et al., 2007). Thymol (500 μM) was shown to activate the transient receptor potential channel (TRPV3) of the tongue and nasal epithelium (Boudry and Perrier, 2008). In transient receptor potential ankyrin1 (hTRPA1) expressing human embryonic kidney cells (HEK293 cells), thymol (6.25 and 25 μM) activated the response of the membrane potential and increased intracellular Ca2+ (Lee et al., 2008). Piglets fed diets supplemented with a combination of thymol (100 and 200 mg/kg) and benzoic acid promoted nutrient digestion and absorption, reduced diarrhea and maintained a favorable micro-environment in the gut (Diao et al., 2015). Thymol (10-3 M) lysed dissociated mouse pancreatic acinar cells as evidenced by increased amylase secretion and the secretion of lactate dehydrogenase (LDH) by 315% (Singh, 1980). A report from Manabe et al. (1987) revealed the biphasic effects of thymol on hypnotic hemolysis. Thymol had a protective effect on erythrocytes at 0.06–1 mM whereas at 2–4 mM it showed a lytic effect on erythrocytes. At a concentration of 1 mM, thymol showed maximum protection for erythrocytes. Thymol (0.2–4 mM) increased the leakage of glutamic oxaloacetate transaminase (GOT) in hepatocytes isolated from male Sprague-Dawley rats. At 33°C, thymol (1 mM) depressed the phase transition temperature and thereby possessed a significant effect on membrane fluidity and it reduced the surface tension from 72 to 53 dye/cm (Manabe et al., 1987). Thymol (0.75–2 mM) triggered the production of superoxide radicals in blood leukocytes in a concentration dependent manner (Suzuki et al., 1987). In guinea pig neutrophils, thymol (1 mM) stimulated superoxide radical production and this was dependent on the initial density of the binding sites and the initial intracellular adenosine triphosphate (ATP) concentrations (Suzuki and Furuta, 1988). Thymol (300 μg/ml) stimulated cytotoxicity whereas treatment with thymol (30–300 μg/ml) dose dependently inhibited the synthesis of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and protein in cultured mammalian cells (Arai, 1988). Thymol (5%) treatment increased the passive transport of leutinizing hormone-releasing hormone (LHRH) in the porcine epidermis (Bhatia and Singh, 1998). The partition coefficient of thymol was assessed to be 1.65 ± 0.01 × 10-2 and at the same concentration it enhanced the permeability of tamoxifen through the porcine epidermis (Gao and Singh, 1998). Thymol (<0.05 mM) suppressed the action potential and reduced membrane resistance and potential in the stomach of guinea pigs at higher concentrations. Thymol (1 mM) inhibited the generation of spikes, hyperpolarized the membrane and resistance in the rectum and ileum (Ito and Kuriyama, 1974). Thymol (0.002 and 0.00015 mol/L) has been shown to induce nerve blocking action in the phrenic nerve of rats (Seeman et al., 1974). In rabbit white muscle, thymol (0.6 mM) induced accumulation of Ca+2 in the sarcoplasmic reticulum (Takishima et al., 1979). Thymol in 0.4% aqueous ethanol has been shown to reduce contractions (ED50= 0.86 × 10-4 M) in the guinea pig ileum induced by acetylcholine (Van den Broucke and Lemli, 1980). Thymol, a Ca2+ antagonist at the concentration of 1 × 10-4 M, also reduced the contractions of rat vas deferens induced by 1-noradrenaline via blocking nerve fiber conductions and inhibited the contractions of guinea pig ileum induced by carbachol, histamine and dimethyl phenyl piperazinium (Van den Broucke and Lemli, 1982). Viana et al. (1981) reported that thymol (2 mg/kg) enhanced the contractions of isolated phrenic-diaphragm and muscles in rats. The same authors revealed that thymol (100 μg) showed potent spasmolytic effects by decreasing the amplitude of peristaltic movements and muscle tone in rabbit duodenum. Thymol (10–300 mg/L) attenuated the force as well as rate of atrial contractions in guinea pigs and at a concentration of 10–300 μg/ml it decreased the aortic contractions isolated from New Zealand white rabbits. Thymol (0.001–0.01%) possessed the ability to relax tension in rabbit intestinal muscles (RIFM 2001, unpublished). Thymol (20 or 40 mg/day) dissolved in olive oil showed clear thyroid activation as detected by oxygen consumption and histological examinations in guinea pigs (Moller, 1939). Thymol (30–300 μg/L) showed a concentration dependent inhibition of DNA, RNA and proteins in V79 cells (Instituto Superiore di Sanita, 1999). Thymol (0.005 M) was shown to possess the ability to convert toxic metals into their non-toxic forms by forming metal complexes or by converting them into their reduced forms by virtue of its antioxidant property (Kishwar et al., 2013). Thymol (200 mg/kg) attenuated Chang’s disease in male Balb/c mice by reducing parasitemia, trypomastigotes, heart amastigotes and inflammatory infiltrates by its anti-Trypanosomaruzi effect (Juan et al., 2015). Supplementation of thymol rich sources like sage, rosemary extracts and pepper improved the digestibility of feed and the final performance in production (Hernandez et al., 2004). Thymol (2 and 3 g/kg) administration improved various growth parameters such as food conversion ratio, final weight, body growth and composition of tissues (whole body lipids, fibers and proteins) (Ahmadifar et al., 2011). Zheng et al. (2009) reported that thymol has a positive effect on the growth performance of channel catfish (Ictalurus panctatus). The presence of thymol might be responsible for the antispasmodic effect of the thyme extract (Engelbertz et al., 2012). Thymol (0–250 μM) showed a weak genotoxic effect in L5178Y/Tk± cells as analyzed by the micronucleus (MN) test and mouse lymphoma (MLA) assays (Maisanaba et al., 2015). Thymol (100 μM) blocked voltage-gated sodium channels in stably transfected HEK 293 cells expressing α-subunit of rat brain IIA or hSkM1 sodium channels and this is attributed to its antinoceptive and anesthetic properties (Haeseler et al., 2002). THYMOL IN CANCER CELLS Thymol showed anticancer properties in different types of cell lines mimicking human cancer and it demonstrated its potential as a chemopreventive or anticancer agent in various types of cancers. The protective effect of thymol against various types of cancers is represented in Table 1 and the schema of the protective effects of thymol shown in the studies is represented in Figure 1. The major mechanisms of anticancer actions of thymol include induction of apoptosis, anti-proliferation, inhibition of angiogenesis and migration as well as the diminution of umourigenesis by modulating the activity of carcinogen metabolizing enzymes. [Table: Effects of thymol in different experimental models of cancer.] [Figure: Schematic representation on the effects of thymol in different experimental models of cancer.] Glioblastoma Cells In human glioblastoma cells, thymol (200–600 μM) produced a rise in (Ca2+)i levels by prompting release of phospholipase C and protein kinase C-dependent Ca2+ from the endoplasmic reticulum (ER) and entry of Ca2+ via non-store-operated Ca2+ channels. Furthermore, the cell death induced by thymol was found to involve apoptosis and necrosis as observed in Annexin V/PI staining (Hsu et al., 2011). Further, thymol (6.0 ± 0.11 mg/g) present in the Zataria multiflora extract possessed radio sensitizing effect in human glioblastoma cells (Aghamohammadi et al., 2015). Glioma Cells Thymol (30 μM) treatment in C6 glioma cells was found to reduce fetal bovine serum induced migration. It also diminished matrix metallopeptidase-9 (MMP9) and matrix metallopeptidase-2 (MMP2) production as well as protein kinase Cα (PKCα) and extracellular signal-regulated kinases (ERK1/2) phosphorylation (Lee et al., 2016). Breast Cancer Cells In breast cancer cells (MCF-7 cells), thymol (0.05–1.25 μM) stimulated cytotoxicity by arresting the cell cycle in the G0/G1 phase (Jaafari et al., 2012). Thymol triggered cytotoxicity in MCF-7 breast cancer cell lines with an LC50 of 2.5 μg/mL (Melo et al., 2014). In another study, Thymol present in the essential oil of T. lanceolatus (IC50= 304.81 μg/ml) was shown to induce cytotoxicity and proliferation in MCF-7 cells (Khadir et al., 2016). Leukemia Cells Thymol (0.05–1.25 μM) suppressed oxidant (H2O2)-induced DNA damage in K-562 cells (Horvathova et al., 2007). The ability of thymol to stop the cell cycle in G0/G1 phase of the K-562 cells seems to be due to its anti-tumor activity (Jaafari et al., 2012). Thymol (5–100 μM) triggers cell death and cell cycle arrest at the sub G0/G1 phase by genomic DNA fragmentation pattern on acute promyelotic leukemia cells (HL-60 cells). Thymol increased the production of ROS and mitochondrial H2O2 thereby depolarizing mitochondrial membrane potential. Thymol treatment induced caspase dependent apoptosis by up-regulating Bcl-2 associated X protein (Bax) expression and down-regulating B-cell lymphoma (Bcl-2) expression in a dose-dependent manner. It further augmented the activation of caspase-3, 8, and 9 concomitant to Poly ADP ribose polymerase (PARP) cleavage that is the hallmark of caspase-dependent apoptosis. Furthermore, it also promoted the translocation of apoptosis inducing factor (AIF) from the mitochondria to cytosol and to nucleus, which shows its ability to induce caspase-independent apoptosis. Altogether, the observations indicate that thymol-induced cell death includes both caspase-dependent and caspase-independent pathways (Dutta et al., 2011). Thymol (0.05–1.25 μM) also induced cytotoxicity mediating cell cycle arrest in the G0/G1 phase of T lymphoblastoid cell line (CEM) (Jaafari et al., 2012). A report from Pathania et al. (2013) has revealed that thymol (30, 50, and 70 μg/ml) suppresses the phosphatidylinositide 3-kinases/Protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway and induced apoptotic cell death mediating both extrinsic and intrinsic pathways in HL-60 cells. A report from Miguel et al. (2015) has revealed that thymol (0–500 μg/ml) triggered an anti- proliferative effect in human acute monocytic leukemia cells (THP-1 cells). A report from Khadir et al. (2016) has revealed that thymol present in Thymus lanceolatus (IC50= 113.51 μM) essential oil triggered cytotoxicity in human leukemia HL-60 cells. Thymol (0.005 μg/ml) present in Thymus vulgaricus abrogated the activity of 5-lipoxygenase (5-LOX) and reduced the expression of cytokines viz. TNF-α, interleukin-1β (IL-1β) and interleukin-8 (IL-8) in THP-1 cells (Tsai et al., 2011). Thymol (400 mg/kg) showed cytotoxicity toward P388 leukemia cells (IC50= 0.8 μg/ml) (Hirobe et al., 1998). Thymol (50 and 200 μg/mL) inhibited inducible lymphocyte proliferation (62.8 and 89.8%) in a concentration dependent manner as the extracts of Thymus vulgaris, Thymus daenensis and Zataria multiflora (Labiatae) were evaluated for their pharmacological effect on mitogen phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes using a cell proliferation assay (Amirghofran et al., 2011). Mastocytoma Cells In P815 mastocytoma cell lines, thymol (0.05–1.25 μM) showed the enhancement of cytotoxicity by arresting the cell cycle in G0/G1 phase (Jaafari et al., 2012). Osteosarcoma Cells In human osteosarcoma cells (MG63 cells), thymol (400 μM/L) treatment induced a rise in the levels of (Ca2+)i by triggering phospholipase C-dependent Ca2+ release from the ER and promoting protein kinase-C sensitive store-operated Ca2+ channels mediated entry of Ca2+. Thymol also triggered ROS mediated apoptotic cell death via mitochondrial pathways in MG63 cells (Chang et al., 2011). Hepatocellular Carcinoma Cells Thymol was shown to inhibit the proliferation of hepatocellular carcinoma (HCC) in the Bel-7402 cell line as analyzed by human 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and acridine orange (AO)/ethidium bromide (EB) florescent staining (Yin et al., 2010). A report from Ozkan and Erdogan (2011) revealed that thymol (10–300 μg/ml) attenuates cytotoxicity in H2O2 induced cytotoxicity and membrane damage via inhibiting lipid peroxidation in hepatoma G2 cells (Hep G2 cells). Thymol (0.1–0.5 mM) showed a protective effect for DNA against H2O2 induced DNA damage in human hepatoma HepG2 cell lines (Horvathova et al., 2014). Thymol (IC50= 497 and 266 mM) was shown to induce DNA damage by increasing the levels of lipid peroxidation products; MDA and 8-hydroxy deoxyguanozine (8-OHdG) in parental and drug resistant human non-small cell lung carcinoma cells (H1299 cell lines). Thymol (